Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.0%

1 terminated out of 20 trials

Success Rate

91.7%

+5.2% vs benchmark

Late-Stage Pipeline

25%

5 trials in Phase 3/4

Results Transparency

18%

2 of 11 completed with results

Key Signals

2 with results92% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (4)
P 1 (2)
P 2 (3)
P 3 (4)
P 4 (1)

Trial Status

Completed11
Unknown4
Not Yet Recruiting2
Active Not Recruiting2
Terminated1

Trial Success Rate

91.7%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT05557539Not ApplicableCompleted

Hypothesizing the Genesis of Infectious Diseases and Epidemics Through an Integrated Systems Biology Approach

NCT06247059Not ApplicableNot Yet Recruiting

Reducing Respiratory Virus Transmission in Bangladeshi Classrooms

NCT06476275Phase 1CompletedPrimary

Single Dose Texas 2017 (H3N2) Challenge Study

NCT06800950Phase 3Not Yet Recruiting

Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

NCT06622590Phase 1Active Not Recruiting

Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

NCT05794412Completed

Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study

NCT05507567Phase 2CompletedPrimary

Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model

NCT04623047Completed

Infection Watch Study

NCT04998344Phase 4Active Not RecruitingPrimary

An Effectiveness Trial to Evaluate Protection of Children and Pregnant Women by Influenza Vaccine in Rural Bangladesh

NCT05234229Completed

Influenza and Pertussis Vaccination Status of Women in Immediate Postpartum and Caregivers

NCT06175468Phase 3UnknownPrimary

Evaluate the Efficacy and Safety of "Formosa 1-Breath Free (NRICM101) " in Subjects With the Symptoms of COVID-19 or Influenza-like Disease

NCT06123936Not ApplicableUnknownPrimary

Impact on Influenza Vaccination Rates of a Telephone Text Message Recall From the Attending Physician

NCT05620953CompletedPrimary

Severe Acute Respiratory Infections (SARI) in Belgium (2011-2020)

NCT05739474Phase 3Unknown

Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children

NCT05869201Phase 2Completed

Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine

NCT05105191Not ApplicableTerminatedPrimary

Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room

NCT03813966CompletedPrimary

Nasal Swab Home Collection Kit (NSHC Kit) Study

NCT01666782Phase 2Completed

Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy

NCT02465190UnknownPrimary

Effectiveness of Trivalent Inactivated Influenza Maternal Vaccination Among Pregnant Women and Their Newborns in South Africa

NCT02103023Phase 3CompletedPrimary

Intradermal Influenza Vaccine in the Young

Showing all 20 trials

Research Network

Activity Timeline